Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules, and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryCannabis
SectorMedical
CIKN/A
Phone855-558-9333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.79 million
Profitability
Miscellaneous
Employees1,033
Next Earnings Date6/26/2019 (Estimated)
OptionableOptionable
Canopy Growth (NYSE:CGC) Frequently Asked Questions
What is Canopy Growth's stock symbol?
Canopy Growth trades on the New York Stock Exchange (NYSE) under the ticker symbol "CGC."
When is Canopy Growth's next earnings date?
What price target have analysts set for CGC?
8 brokerages have issued 12-month price targets for Canopy Growth's stock. Their predictions range from $46.27 to $61.00. On average, they anticipate Canopy Growth's share price to reach $55.7567 in the next year. This suggests a possible upside of 25.6% from the stock's current price. View Analyst Price Targets for Canopy Growth.
What is the consensus analysts' recommendation for Canopy Growth?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Canopy Growth in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Canopy Growth.
Has Canopy Growth been receiving favorable news coverage?
News coverage about CGC stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Canopy Growth earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned press coverage about the marijuana producer a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Canopy Growth's key competitors?
Some companies that are related to Canopy Growth include Actelion (ALIOF), Aurora Cannabis (ACB), Tilray (TLRY), STADA Arzneimittel (STDAF), Cronos Group (CRON), USANA Health Sciences (USNA), CV Sciences (CVSI), Canopy Rivers (RIV), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX) and Cyanotech (CYAN).
What other stocks do shareholders of Canopy Growth own?
Who are Canopy Growth's key executives?
Canopy Growth's management team includes the folowing people:
- Bruce Linton, Chairman & Co-Chief Executive Officer
- Mark Zekulin, President & Co-Chief Executive Officer
- Timothy R. Saunders, Chief Financial Officer & Executive Vice President
- Amanda Daley, Vice President-Medical
- Ru Wadasinghe, Chief Information Officer
Who are Canopy Growth's major shareholders?
Canopy Growth's stock is owned by a variety of of retail and institutional investors. Top institutional investors include ETF Managers Group LLC (0.64%), Connor Clark & Lunn Investment Management Ltd. (0.63%), Macquarie Group Ltd. (0.57%), Norges Bank (0.49%), TD Asset Management Inc. (0.34%) and Bank of Nova Scotia (0.17%).
Which major investors are selling Canopy Growth stock?
CGC stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, D. E. Shaw & Co. Inc., Connor Clark & Lunn Investment Management Ltd., Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Bank of America Corp DE, Essex Investment Management Co. LLC, Two Sigma Advisers LP and Macquarie Group Ltd..
Which major investors are buying Canopy Growth stock?
CGC stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Norges Bank, Bank of New York Mellon Corp, Bank of Nova Scotia, Legal & General Group Plc, Intact Investment Management Inc., Mackenzie Financial Corp and Aviva PLC.
How do I buy shares of Canopy Growth?
Shares of CGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Canopy Growth's stock price today?
One share of CGC stock can currently be purchased for approximately $44.38.
How big of a company is Canopy Growth?
Canopy Growth has a market capitalization of $14.85 billion and generates $60.79 million in revenue each year. The marijuana producer earns $-54,880,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Canopy Growth employs 1,033 workers across the globe.
What is Canopy Growth's official website?
How can I contact Canopy Growth?
Canopy Growth's mailing address is 1 HERSHEY DRIVE, SMITH FALLS A6, K7A0A8. The marijuana producer can be reached via phone at 855-558-9333 or via email at [email protected]
MarketBeat Community Rating for Canopy Growth (NYSE CGC)
MarketBeat's community ratings are surveys of what our community members think about Canopy Growth and other stocks. Vote "Outperform" if you believe CGC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGC will underperform the S&P 500 over the long term. You may vote once every thirty days.
